Navigation Links
Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial

e Dietrich +44 (0)20 7466 5000 Buchanan Communications

Brian Korb +1 646 378 2923 The Trout Group

Antisoma disclaimer Certain matters discussed in this statement are forward looking statements that are subject to a number of risks and uncertainties that could cause actual results to differ materially from results, performance or achievements expressed or implied by such statements. These risks and uncertainties may be associated with product discovery and development, including statements regarding the company's clinical development programmes, the expected timing of clinical trials and regulatory filings. Such statements are based on management's current expectations, but actual results may differ materially.

Details of the ASA404 trial in ovarian cancer The ASA404 trial in ovarian cancer included women with ovarian cancer that had recurred six months or more after treatment with platinum chemotherapy. Patients were randomised to receive either ASA404 plus carboplatin and paclitaxel chemotherapy or the chemotherapy drugs alone.

Endpoints measured in the trial included response (a measure of tumour shrinkage), which was assessed both by the doctors participating in the trial and by an independent analysis of patient scans; time to tumour progression (a measure of the time between treatment and the resumption of tumour growth); and survival.

Thirty-seven patients were treated in the ASA404 arm and 38 received chemotherapy alone. One patient in the ASA404 arm was excluded from the analysis of survival and one patient in the chemotherapy-alone arm was excluded from the independent analyses of response and time to tumour progression.

The data from the ovarian cancer study will be presented by Prof Hani Gabra of Imperial College, London, at the ECCO (European Cancer Conference) in Barcelona on September 26th 2007. This will be a poster presentation in the Gynaecological Cancer session (1400-1700 CET; title: Update of phase II stu
'"/>




Page: 1 2 3

Related medicine technology :

1. Data supporting three Antisoma programmes presented at AACR
2. Antisoma plc (UK) - Second lung cancer trial adds to positive data on AS1404
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
(Date:11/6/2009)...wswire/ -- Philips Respironics applauds the effort...n (CDC) to raise awareness about an important publ...e CDC,s release of the first-ever government study...sness is a milestone in quantifying the size and s...r, industry leader and sleep therapy manufacturer,...
(Date:11/6/2009)...irstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasda... November 10, 2009 at 8:30 a.m. EST to discuss the... outlook for the remainder of 2009. Ron Bentsur, ...the call. Keryx will announce its financial resul... prior to the call. ,, In order to participate ...
(Date:11/6/2009)...rstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board...ased, biopharmaceutical company developing human v...deficiency Virus) and other infectious agents, tod...lts and provided an operational update. ,, Robe...fficer commented, "We are pleased with our progres...
Breaking Medicine Technology:Statement by Don Spence, CEO, Philips Home Healthcare Solutions, Endorsing CDC Educational Initiatives to Raise Awareness of Sleep Deprivation 2Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST 2GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 2GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 3GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 4GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 5GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 6GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 7GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 8ISTA Pharmaceuticals to Present at 2009 BIOCOM Investor Conference 5600 1Babies Injured in Car Seats Used Outside of Cars 59817 1Babies Injured in Car Seats Used Outside of Cars 59817 2Babies Injured in Car Seats Used Outside of Cars 59817 3Henk Stunnenbergs lab applies Genomatix NextGen sequencing data analysis 59814 1
...d Regulatory Approval for Three Phase II Cancer ...hemotherapy --, -- New Clinical Trial Will Evaluat... Combination with Carboplatin and Paclitaxel --, ...s, Inc. (Nasdaq: PPHM ), a clinical stage biophar...s for the treatment of cancer and,hepatitis C viru...
...roMetrix, a global leader in,quality control mater...ounced today that it will extend its contract with...) through December 31st of 2009. Following,the pre...recommend and,promote AcroMetrix as a recommended ...77 members across the US and Canada., "Because of...
Other Medicine Technology:Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer 2Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer 3Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer 4AcroMetrix Renews Contract With Group Services for America's Blood Centers 2
(Date:11/7/2009).../ -- The American Medical Association (AMA) today ...ip and Community Service to Manus C. Kraff, M.D., ...ognizes physicians who have gone above and beyond ...ding public service contribution to their local co... the opening session of the 2009 Interim Meeting o...
(Date:11/7/2009)... -- Members of the AMA are trying a last-minute ta...ng the AMA,s support of HR 3962. ,, "We want t...heir PATIENTS, not the leadership of the AMA," sai...iation of American Physicians and Surgeons, and Ta...ups. ,, "If the AMA leadership ignores the pub...
(Date:11/7/2009)...re/ -- Speaker Nancy Pelosi and Democratic leaders...g a Democratic Whip meeting with President Obama i... opening remarks: ,, "Thank you very much, Mr....eive the President of the United States on this da... making progress for the American people. ,, ...
(Date:11/7/2009)...cross the U.S. , , SATURDAY, Nov. 7 (Healt... colleges do it regularly (and, it,s not sex). , R... alcoholic drinks at a sitting. , "People have a h...y Hwang, associate dean of students and director o...on Long Island, N.Y. In fact, she said, heavy drin...
(Date:11/7/2009)...m Greensations fights pain and increases circulati...rmaFeet targets foot pain and soreness with a soot...ut, Goldenseal, Vitamin C and Alpha Lipoic Acid. ,...) November 7, 2009 -- A new foot spray from Greens...the power of hot peppers and caffeine. The main pa...
Breaking Medicine News(10 mins):Health News:AMA Honors IL Ophthalmologist Manus C. Kraff M.D. for Volunteer Eye Care for Military Members 2Health News:Pelosi Remarks Following House Democrats' Meeting with President Obama 2Health News:Binge Drinking Puts the Brain, and Life Itself, at Risk 2Health News:Binge Drinking Puts the Brain, and Life Itself, at Risk 3Health News:Hot Peppers and Caffeine Relieve Painful Feet, Toe Fungus and Foot Odor 2
...ges C. Benjamin, MD, FACP, FACEP (E), Executive D...HINGTON, July 30 The American Public,Health Assoc...for today,passing the Family Smoking and Tobacco C...d and Drug,Administration (FDA) the authority to r...
... The U.S. House of,Representatives today took a h...that grants the U.S. Food and Drug Administration ...he authority to crack down on,tobacco marketing an...Senator Sherrod Brown (D-OH) voted for the bill,la...
...ation to give FDA needed regulatory authority over...wing is a,statement by Joseph Heyman, M.D., Board ... U.S. House of Representatives took a critical ste...co,products. We hope members of the U.S. Senate wi...
... 30 Today, Congresswoman,Stephanie Tubbs Jones re...,Prevention and Tobacco Control Act. This legislat...roducts to protect the public health and will,crea...essation programs targeted at cutting the rate of ...
... BioMed Realty Trust, Inc.,(NYSE: BMR ), a real e...state to the life science industry, today announce...une 30, 2008., Highlights:, -- Funds from opera...ross leasing volume of approximately 327,000 s...
... back by petitioning NLRB for election to win,repr... STANFORD, Calif., July 30 Continuing its,long-s...p was to withdraw,union recognition. Undeterred in...for a union election. UHW already,represents most ...
Other Medicine News:Health News:House Passes Historic Bill to Protect Kids From Tobacco; Senator Voinovich Should Cosponsor Legislation 2Health News:BioMed Realty Trust Reports Second Quarter 2008 Financial Results 2Health News:BioMed Realty Trust Reports Second Quarter 2008 Financial Results 3Health News:BioMed Realty Trust Reports Second Quarter 2008 Financial Results 4Health News:BioMed Realty Trust Reports Second Quarter 2008 Financial Results 5Health News:BioMed Realty Trust Reports Second Quarter 2008 Financial Results 6Health News:BioMed Realty Trust Reports Second Quarter 2008 Financial Results 7Health News:BioMed Realty Trust Reports Second Quarter 2008 Financial Results 8Health News:BioMed Realty Trust Reports Second Quarter 2008 Financial Results 9Health News:BioMed Realty Trust Reports Second Quarter 2008 Financial Results 10Health News:BioMed Realty Trust Reports Second Quarter 2008 Financial Results 11Health News:BioMed Realty Trust Reports Second Quarter 2008 Financial Results 12Health News:BioMed Realty Trust Reports Second Quarter 2008 Financial Results 13
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
Medicine Products: